The hard truth is that HCM, like other genetic cardiomyopathies, diminishes quality of life and survival. We can only substantively change natural history by understanding the fundamental mechanisms of disease and developing disease-modifying therapies. To mistake palliation for cure is inappropriate. Much remains to be learned and we hope that SHaRe continues to stimulate a call to action: To work collaboratively and tirelessly to target and correct the molecular abnormalities at the core of HCM, to improve the lives of our patients and families.
Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)" / Ho C.Y., Day S.M., Ashley E.A., Michels M., Pereira A.C., Jacoby D., Lakdawala N.K., Ware J.S., Helms A.S., Colan S.D., Seidman C.E., Olivotto I.. - In: CIRCULATION. - ISSN 1524-4539. - ELETTRONICO. - 139:(2019), pp. 1559-1560. [10.1161/CIRCULATIONAHA.118.039069]
Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)"
Pereira A. C.;Olivotto I.
2019
Abstract
The hard truth is that HCM, like other genetic cardiomyopathies, diminishes quality of life and survival. We can only substantively change natural history by understanding the fundamental mechanisms of disease and developing disease-modifying therapies. To mistake palliation for cure is inappropriate. Much remains to be learned and we hope that SHaRe continues to stimulate a call to action: To work collaboratively and tirelessly to target and correct the molecular abnormalities at the core of HCM, to improve the lives of our patients and families.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



